SEC Company Response from PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101) (PLSE) — Nov 2, 2018
PULSE BIOSCIENCES, INC. (PLSE) (CIK 0001625101)
Date: Nov. 2, 2018 · CIK: 0001625101 · Accession: 0001625101-18-000054
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227974
Letter
SEC Acceleration Request (11-2-2018)
November 2, 2018
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention:
Amanda Ravitz
Timothy Buchmiller
Re:
Pulse Biosciences, Inc.
Registration Statement on Form S-3
Filed October 25, 2018
File No. 333-227974
Acceleration Request
Requested Date:
November 6, 2018
Requested Time:
4:00 PM Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-227974) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf.
The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, at (650) 849-3240.
Please direct any questions or comments regarding this acceleration request to Andrew D. Hoffman at (650) 849-3240.
*****
Securities and Exchange Commission
Re: Pulse Biosciences, Inc.
November 2, 2018
Page 2
Sincerely,
Show Raw Text
CORRESP 1 filename1.htm SEC Acceleration Request (11-2-2018) November 2, 2018 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Amanda Ravitz Timothy Buchmiller Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 Filed October 25, 2018 File No. 333-227974 Acceleration Request Requested Date: November 6, 2018 Requested Time: 4:00 PM Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pulse Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-227974) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company may request by telephone to the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf. The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Andrew D. Hoffman of Wilson Sonsini Goodrich & Rosati, Professional Corporation, at (650) 849-3240. Please direct any questions or comments regarding this acceleration request to Andrew D. Hoffman at (650) 849-3240. ***** Securities and Exchange Commission Re: Pulse Biosciences, Inc. November 2, 2018 Page 2 Sincerely, PULSE BIOSCIENCES, INC. By: /s/ Brian B. Dow Brian B. Dow Senior Vice President and Chief Financial Officer cc: Andrew D. Hoffman, Esq. Wilson Sonsini Goodrich & Rosati, Professional Corporation